Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 30 out of 100. Risk genes beyond APOE

Topic: Brain proteins, microglia and lab models

Plain-language summary

HIIT alone and in combination with CBD treatment significantly improved cognitive impairment induced by AD. Moreover, both treatments significantly reduced BACE1 protein expression and increased nestin protein expression in AD rats. However, despite decreased miRNA-124 expression levels in the AD group in comparison with the CNT group, HIIT and CBD administration did not alter miRNA-124 expression levels in other groups. The findings can contribute to a higher understanding of the beneficial effects of HIIT combined with CBD administration in mitigating AD-induced cognitive impairment by reducing BACE1 protein expression and increasing nestin protein expression.

What this study adds

Evidence grade: Low

In a rat model of Alzheimer's disease, high-intensity interval training alone and combined with cannabidiol improved cognitive impairment and reduced BACE1 while increasing nestin, but neither treatment changed miRNA-124 levels. These are animal findings and do not establish a treatment for people.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Kordi, M. R., Kooshan, A. R., Jafari-Hokmabadi, S. P., Gaeini, A. A., & Zobeydi, A. M. (2026). Combating cognitive decline in a rat model of Alzheimer’s disease: The role of high-intensity interval training and cannabidiol administration in modulating microRNA-124, BACE1, and nestin. Current Journal of Neurology. https://doi.org/10.18502/cjn.v24i3.21601

Vancouver

Kordi MR, Kooshan AR, Jafari-Hokmabadi SP, Gaeini AA, Zobeydi AM. Combating cognitive decline in a rat model of Alzheimer’s disease: The role of high-intensity interval training and cannabidiol administration in modulating microRNA-124, BACE1, and nestin. Current Journal of Neurology. 2026. doi:10.18502/cjn.v24i3.21601. PMID: 42634764.

BibTeX

@article{kordi2026-42634764,
  author  = {Kordi, Mohammad Reza and Kooshan, Amir Reza and Jafari-Hokmabadi, Seyed Pouya and Gaeini, Abbas Ali and Zobeydi, Amir Mohammad},
  title   = {{Combating cognitive decline in a rat model of Alzheimer’s disease: The role of high-intensity interval training and cannabidiol administration in modulating microRNA-124, BACE1, and nestin}},
  journal = {Current Journal of Neurology},
  year    = {2026},
  doi     = {10.18502/cjn.v24i3.21601},
  pmid    = {42634764},
  url     = {https://doi.org/10.18502/cjn.v24i3.21601}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In a rat model of Alzheimer's disease, high-intensity interval training alone and combined with cannabidiol improved cognitive impairment and reduced BACE1 while increasing nestin, but neither treatment changed miRNA-124 levels. These are animal findings and do not establish a treatment for people.

Study details

How this study scored 30/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 1 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 29 of the 96 points it could be judged on, which is 30 of 100. Total 30 of 100.29 of the 96 points we could judge = 30 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 29 of the 96 points we could judge it on, which is 30 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Current Journal of Neurology)
Journal's citation record 0 / 4 Current Journal of Neurology: journal h-index 16 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Laboratory or animal study (title names “rat”) — scores zero
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Amir Mohammad Zobeydi holds only 7 work(s), too few to judge a track record — left out of this score
Institution's track record 1 / 3 Ruhr University Bochum: institution h-index 704 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 42634764)
Free to read 2 / 2 Free to read
Points 29 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 29 of the 96 points we could judge it on is 30 out of 100.
Total 30 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Risk genes beyond APOE from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Risk genes beyond APOE

See all studies in Risk genes beyond APOE →